Parkinson's disease: Prospects for improved drug therapy

Jim J. Hagan, Derek N. Middlemiss, Paul C. Sharpe, George H. Poste

Research output: Contribution to journalReview articlepeer-review

90 Scopus citations


L-Dopa has long been the mainstay of therapy for Parkinson's disease but its long-term shortcomings, principally uncoordinated, spasmodic or irregular movements (dyskinesias) and fluctuating control of motor symptoms (on/off fluctuations), are well documented. The postulated neuroprotective properties of L-deprenyl, often used as an adjunct to L-dopa, are under scrutiny and doubts have also been raised regarding its safety. Alternative therapeutic approaches are clearly needed. In this review, Jim Hagan, Derek Middlemiss, Paul Sharpe and George Poste outline some new approaches to treatment, with an emphasis on novel, selective dopamine receptor agonists. In addition, Parkinson's disease is commonly thought to be caused by the neurotoxic effects of an unidentified agent but recent data indicate a greater genetic component than previously recognized. Developments in the genetics of Parkinson's disease may provide the key to the next generation of therapeutics.

Original languageEnglish (US)
Pages (from-to)156-163
Number of pages8
JournalTrends in Pharmacological Sciences
Issue number5
StatePublished - May 1 1997
Externally publishedYes

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Parkinson's disease: Prospects for improved drug therapy'. Together they form a unique fingerprint.

Cite this